Intrepid’s Healthcare Group continues to see a high volume of consolidation activity across all segments of healthcare. An extraordinary breadth of strategic acquirers and financial sponsors are seeking M&A targets… Read more »
While hot sectors like ophthalmology, dermatology, genetics, and behavioral health continue to draw a lot of attention in the media, we are seeing an emerging group of middle-market private equity… Read more »
The 2019 Executive War College Conference on Lab and Pathology Management generated record attendance with meeting rooms filled by senior leaders from diagnostic labs from across the world. We believe… Read more »
Due to the advent of consumer-directed healthcare, Intrepid’s Healthcare team is seeing meaningful changes develop in the key value attributes that distinguish premium-priced healthcare companies. As business owners and investors… Read more »
As we head into the homestretch of 2018, Intrepid’s Healthcare Group is happy to share with you some of the deals and trends drawing our attention amid a crowded M&A… Read more »
Will healthcare dealmakers take summer vacations? They may need to after a particularly active healthcare M&A season in Q2’18. Macro M&A trends combined with sector-specific healthcare deal drivers were a… Read more »
Following several high-profile, silo-shattering mergers and acquisitions in the healthcare industry, many healthcare investors are questioning what might be the next paradigm shift and how these large-scale transactions will affect… Read more »
The third quarter of 2017 ended on a high note for our Healthcare team as we closed the sale of Ambry Genetics to Konica Minolta in a deal valued at… Read more »
In this issue, we analyze a select group of exciting recent healthcare transactions that caught our attention. We highlight a recent increase in large-scale hospital transactions, describe a merger that… Read more »